Leker Ronen R, Aharonowiz Michal, Greig Nigel H, Ovadia Haim
Department of Neurology, the Agnes Ginges Center for Human Neurogenetics, Hebrew University-Hadassah Medical School, Hadassah University Hospital, Ein Kerem, Jerusalem 91120, Israel.
Exp Neurol. 2004 Jun;187(2):478-86. doi: 10.1016/j.expneurol.2004.01.030.
No neuroprotective compounds are clinically available for the treatment of ischemic stroke. The potential salutary effect of pifithrin alpha, a novel-specific inhibitor of the transcription factor p53, administered 1-6 h following focal reversible cerebral ischemia, was investigated. Studies measuring histological, motor, and behavioral outcomes showed significant improvements in pifithrin alpha-treated animals. Pifithrin alpha reduced the number of apoptotic cells in the ischemic brain by inhibiting the binding of p53 to its DNA sites as it reduced the expression of the p53-related gene p21(WAF) without changing the amount of p53 protein itself.
目前临床上尚无神经保护化合物可用于治疗缺血性中风。研究了在局灶性可逆性脑缺血后1 - 6小时给予新型特异性转录因子p53抑制剂匹非尼酮α的潜在有益作用。测量组织学、运动和行为结果的研究表明，匹非尼酮α治疗的动物有显著改善。匹非尼酮α通过抑制p53与其DNA位点的结合，减少了缺血脑中凋亡细胞的数量，因为它降低了p53相关基因p21（WAF）的表达，而不改变p53蛋白本身的量。
Zotero 插件